Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differential expression genes analysis in MC38/gp100 cell line with DMSO or type I PRMT inhibitor treatment

ABSTRACT: Differential expression genes analysis in MC38/gp100 cell line with DMSO or type I PRMT inhibitor treatment

PROVIDER: PRJNA679894 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13092382_1.fastq.gz	Fastqsanger.gz
	SRR13092382_2.fastq.gz	Fastqsanger.gz
	SRR13092383_1.fastq.gz	Fastqsanger.gz
	SRR13092383_2.fastq.gz	Fastqsanger.gz
	SRR13092384_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

MC38/gp100 cells after type I PRMT inhibitor treatment

Project description:MC38/gp100 cells after type I PRMT inhibitor treatment

| PRJNA679810 | ENA

Chromatin accessibility in MC38/gp100 cells after type I PRMT inhibitor treatment

Project description:Chromatin accessibility in MC38/gp100 cells after type I PRMT inhibitor treatment

| PRJNA679893 | ENA

Differential expression genes analysis in MC38/gp100 cell line with DMSO or type I PRMT inhibitor treatment

Project description:Immunotherapies have produced dramatic responses in reducing tumor growth and prolonging overall survival to unprecedented rates in melanoma, lung cancer, renal cancer and mismatch repair deficient colon cancer patients. Despite approvals for immune checkpoint inhibitors in a wide range of cancers, the majority of patients’ relapse following initial response to immunotherapy or fail to respond altogether. These failures can be attributed to an insufficient immune response against tumors and/or mechanisms co-opted by tumor cells to produce a suppressive tumor microenvironment. Therefore, identification of combination strategies to enhance the response rates of immunotherapies to a broader patient population are the current subject of intensive basic and clinical research. Type I PRMTs have been described as regulators of immune response pathways in several cell types by direct arginine methylation on specific substrates, as well as through indirect mechanisms. Recent work has suggested that arginine methylation may have a role in tumor immunity, yet these roles remain poorly understood. Using the skin cutaneous melanoma (SKCM) TCGA dataset, we show that increased expression of Type I PRMTs is associated with poor clinical response and decreased immune infiltration in melanoma patients. Through a series of preclinical tumor models, we demonstrate that inhibition of Type I PRMTs can increase hallmarks of an inflamed tumor microenvironment and sensitivity to inhibition of the PD-(L)1 signaling axis. Accordingly, Type I PRMT inhibition synergizes with immune checkpoint blockade to induce durable and effective antitumor responses in an array of immunocompetent tumor models. These data provide a rationale to combine Type I PRMT inhibitors with checkpoint blockade to maximize clinical benefit in cancer patients.

2022-11-01 | GSE161908 | GEO

Chromatin accessibility in MC38/gp100 cells after type I PRMT inhibitor treatment

2022-11-01 | GSE161909 | GEO

MC38/gp100 cells after type I PRMT inhibitor treatment

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-11-01 | GSE161910 | GEO

Differential expression genes analysis of knocking down Prmt1 and Ripk1 in MC38/gp100 cell line

Project description:Differential expression genes analysis of knocking down Prmt1 and Ripk1 in MC38/gp100 cell line

| PRJNA678452 | ENA

RNA-seq of parental MC38 and anti-PD-1 resistant MC38 subcutaneous tumors

Project description:MC38 tumors resistant to anti-PD-1 treatment (MC38-resistant) were generated through serial in vivo passaging, and global gene expression analysis was used to compare resistant and parental tumors. MC38 and MC38-resistant tumors exhibited widespread changes in global gene expression.

2021-07-22 | GSE180309 | GEO

Immunopeptidome on MC38 Cell line

Project description:PTM – driven antigenicity – immunopeptidome of MC38 cell line

2022-10-12 | PXD017448 | Pride

Complete genome of Pseudomonas phage GP100

Project description:Complete genome of Pseudomonas phage GP100

| PRJEB23522 | ENA

A TCR/anti-CD3 bispecific fusion protein targeting gp100 potently activated anti-tumor immune responses in metastatic melanoma

Project description:Tumor-specific cytotoxic T cells are required for effective immunotherapy. Here we introduce a bispecific fusion protein (tebentafusp) designed to target gp100 (a melanoma-associated antigen) through a high affinity T cell receptor binding domain, and through an anti-CD3 effector domain re-directs any cytotoxic T cell, regardless of its intrinsic specificity, to kill gp100-expressing tumor cells. In patients with metastatic melanoma, tebentafusp showed anti-tumor activity and manageable and predictable side effects. Notably, tebentafusp induced an increase in serum CXCL10 (a T cell attractant), and a reduction in circulating CXCR3+ CD8+ T cells together with an increase in cytotoxic T cells in the tumor microenvironment (TME). Furthermore, the appearance of rash, likely due to cytotoxic T cells targeting of gp100-expressing skin melanocytes, or an increase in serum CXCL10 showed a positive association with patient survival. Taken together, these results suggest that re-directing T cells using a gp100-targeting T cell receptor/anti-CD3 bispecific fusion protein may provide benefit to patients with metastatic melanoma.

2019-10-30 | GSE139566 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data